Introduction The global pandemic of coronavirus disease 2019 (COVID‐19) is caused by the
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). It seems that there is an …

Extensive research in countries with high sociodemographic indices (SDIs) to date has
shown that coronavirus disease 2019 (COVID-19) may be directly associated with more …

Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are …

Vaccination guidelines for patients treated for hematological diseases are typically
conservative. Given their high risk for severe COVID-19, it is important to identify those …

During the inflammatory response, macrophage phenotypes can be broadly classified as
pro-inflammatory/classically activated “M1”, or pro-resolving/alternatively “M2” …

Background CD8+ T cells play an essential role against tumors but the role of human CD8+
CD26+ T cell subset against tumors, in particular, haematological cancers such as chronic …

Background Cancer patients particularly those with hematological malignancies are at
higher risk of affecting by severe coronavirus disease 2019 (COVID-19). Due to the …

Lymphoid hematologic malignancies (HMs) and their treatment may result in secondary
antibody deficiency (SAD), which is associated with an increased risk and susceptibility for …

Simple Summary Taking into consideration the high risk of patients with cancer for severe
COVID-19 infection, prioritization has been given to primary prevention with both primary …

Primary and secondary immunodeficiencies cause an alteration in the immune response
which can increase the rate of infectious diseases and worsened prognoses. They can also …